GenSyn Technologies, Inc. provides customized solutions for the particle engineering challenges faced by its pharmaceutical clients. GenSyn Technologies’ research and development scientists work as strategic partners with clients to apply GenSyn Technologies’ Crystal Control Technology™ to provide more efficient and reproducible drug formulations. Through its unique control of particle size, shape and distribution, Crystal Control Technology™ allows clients to achieve their optimal particle specifications. GenSyn Technologies is dedicated to improving bioavailability and expanding drug delivery options of small molecule API’s with its proprietary particle engineering.
Allan S. Myerson, Ph.D., Scientific Advisory Board Chair, Board Director
Allan S. Myerson heads the Scientific Advisory Board of GenSyn Technologies. His expertise lies within separation processes in the chemical and pharmaceutical industry with an emphasis on crystallization from solution. He has published 5 books including the “Handbook of Industrial Crystallization,” 200 papers, and is the inventor on 37 US patents.
Allan is Professor of the Practice of Chemical Engineering in the Department of Chemical Engineering at the Massachusetts Institute of Technology. Prior to his position at MIT, he was the Philip Danforth Amour Professor of Engineering in the Department of Chemical and Biological Engineering at the Illinois Institute of Technology (IIT) in Chicago where he served as Provost and Senior Vice President (January 2003-June 2008) and Dean of Engineering and Science (January 2000-January 2003). Professor Myerson also served on the faculty at Polytechnic University (NY), Georgia Institute of Technology and the University of Dayton.
Allan serves as a co-principal investigator in the Novartis-MIT Center for Continuous Manufacturing and as associate editor of “Crystal Growth and Design” a journal published by the American Chemical Society. In addition to GenSyn Technologies, Inc., he is a member of the Scientific Advisory Boards of Continuus Pharmaceuticals and Blue Spark Technologies. Allan has consulted for approximately 100 companies worldwide and was honored in 2008 with the American Chemical Society Award in Separations Science and Technology.
Allan was educated at Columbia University (B.S.) the University of Virginia (M.S. and Ph.D.).
Ethan Cohen, Chief Executive Officer, Chairman of the Board
Ethan Cohen is the CEO of GenSyn Technologies. He has a long career serving in executive management positions associated with healthcare and technology.
Prior to joining GenSyn, Ethan was CEO of Easy2 Technologies, a leading provider of interactive merchandising solutions that was acquired by Answers Corporation. During 2010, he served as an Executive in Residence for the Cleveland Clinic with a focus on commercializing emerging healthcare information technologies. Prior to this, Ethan was the President of SPi Healthcare, a provider of medical transcription services with operations in the US, the Philippines and India. Ethan also worked in teleradiology services where he served as the Chief Executive Officer of Telerad Express and the COO of Franklin & Seidelmann. From 1997 until 2004, Ethan was the Chief Technology Officer of MedQuist, the world’s largest medical transcription service, and he also served as a Senior Engagement Manager for McKinsey & Company, an international, management consulting firm.
Ethan has an M.B.A. from the Harvard Business School, where he graduated with Distinction, and an A.B. in Applied Mathematics from Harvard College, where he graduated Summa Cum Laude.
Stephen DaVanzo, Ph.D., Chief Scientific Officer
Steve DaVanzo, Ph.D. is the Chief Scientific Officer of GenSyn Technologies. He has a long career serving in both management and scientific positions.
Steve has held senior technical and management roles in scientific and product development for Dow Chemical, BP/Carborundum, Advanced Ceramics Corporation and Five Star Technologies. As an independent consultant he provided scientific advisory services to an international audience of companies. Steve spent six years developing cavitation technology. Steve’s broad material science and particle engineering background provide a unique set of insights to scalable nano-technologies and stabilizations.
Steve received his Ph.D. from The Pennsylvania State University, an EMBA from Northwestern University and a B.S. in Physics from Southern CT State University.
Kelly Newton, Vice President, Business Development
Kelly Newton is Vice President of Business Development for GenSyn Technologies. Prior to joining GenSyn in 2012, Kelly worked with GenSyn’s lead venture capital investor, Early Stage Partners. From 2008 to 2010 Kelly was an investment analyst at an endowment-style investment management firm, HighVista Strategies. Kelly started off her career at Bank of America’s Global Corporate Investment Bank, working across a range of industries as an Analyst promoted to Associate from 2004 to 2007.
Kelly has an M.B.A. from Northwestern University’s Kellogg School of Management and a B.S. in Business Administration and Information Science from the University of North Carolina at Chapel Hill, where she graduated with Honors.
Nancy G. Rubin, Chief Financial Officer
Nancy Rubin is Chief Financial Officer for GenSyn Technologies. Nancy is a senior financial executive with over 25 years of diverse experience, including strategic planning, business development, finance, accounting, operations, and marketing. The size and types of companies with whom Nancy has worked have ranged from early stage, privately-held concerns to complex, publicly-traded Fortune 100 companies in different industries such as biomedical products, automotive and industrial components manufacturing, food manufacturing and distribution, financial services and healthcare services.
Nancy holds an M.B.A. from Cleveland State University and a B.B.A. from Kent State University.